 |
Translational medicine : the future of therapy? / edited by James Mittra, Christeopher-Paul Milne. -- Singapore : Pan Stanford, c2013. – (58.042/T772) |
Contents
CONTENTS
Preface
PART 1 INTRODUCTION
1 Introduction to Translational Medicine
1.1 What Is Translational Medicine and Where Did It Come From?
1.2 Different Drivers and Expectations of Translational Medicine
1.3 General Aims and Scope of This Book
1.1 Overview of Chapters
PART 2 DRIVERSAND BARRIERS TO TRANSLATIONAL MEDICINE
2 New Light Through an Old Window? The "Translational Turn" in Biomedical Research: A Historical Perspective
2.1 Introduction
2.2 Bridging Clinic and Lab: The Physician-Scientist
2.3 The Physician-Scientist: An "Endangered Species"?
2.4 Conclusion
3 Translational Medicine: The Industry Perspective
3.1 Introduction
3.2 Translational Medicine Drivers
3.3 Biomarkers， Bioimaging， Bioinformatics: Industrial Strength TM Tools
3.4 Case Studies
3.5 Future Directions
4 Drivers and Barriers of TM: A Regulatory Perspective
4.1 Introduction
4.2 Drivers of TM
4.3 Impact of TM on Regulatory Decision Making and Barriers to TM
4.4 Concluding Remarks
5 Developing an Evaluation Model for Translational Medicine Research Programs
5.1 Introduction and Background
5.2 Preparing to Build the Evaluation Model
5.3 Identifying and Analysing Definitions of TMR
5.4 Applying Systems Thinking to the Model
5.5 Building the Evaluation Model
5.6 Piloting the Evaluation Model
5.7 Additional Comment on Definitions
5.8 Implications for Future Evaluation of TMR
PART 3 STATE-OF-THE-ART IN THE SCIENCE AND TECHNOLOGY
6 Emerging Concepts in Biomarker Discovery: Cancer Immunotherapy and Degenerative Disease of the Eye as Model Systems 129
6.1 Introduction
6.2 What Is a Biomarker?
6.3 Discussion and Conclusions
7 Imaging Biomarkers for Innovative Drug Development: Translation from Bench to Bedside and Back
7.1 Introduction
7.2 The Different Types of Imaging Biomarkers
7.3 Experience of Imaging Biomarker Clinical Translation for Select Diseases
7.4 Challenges for Clinical Translation and Optimization of Imaging Biomarkers
7.5 Conclusions and Future Outlook
8 Translational Bioinformatics: Bridging the Biological and Clinical Divide
8.1 Introduction
8.2 A Genomic Revolution or Avalanche?
8.3 The Clinical Data Deluge
8.4 Developing the Bridge Between Biological and Clinical Data
8.5 A Look at the Future
8.6 Concluding Remarks
PART 4 INSTITUTIONAL DYNAMICS OF TRANSLATIONAL MEDICINE
9 Exploiting Translational Medicine Through Public-Private Partnerships: A Case Study of Scotland's Translational Medicine Research Collaboration
9.1 Introduction and Background
9.2 History and Background to TMRC
9.3 Organizational Structure of the Initiative
9.4 Principal Objectives and Contribution to Improving Life Science Innovation
9.5 Key Challenges Facing the Collaboration and Response to Loss of Follow-on Funding
9.6 Further Reflections on the Failure of TMRC
9.7 Conclusion: Lessons to be Learned from the TMRC
Experience
10 The Role of the Product Development Partnership as a Translational Mechanism for Delivering Health Solutions in Low-Resource Settings
10.1 Introduction
10.2 Background and Context
10.3 Innovating for Health and the Growth of PDPS
10.4 The Funding Context
10.5 PDPS as Social and Organizational Experiments in TM
10.6 Understanding the Integrator and Broker Framework
10.7 The Changing Global Health Landscape
10.8 IAVI in Developing Countries
10.9 Discussion and Conclusions
PART 5 CONCLUSIONS
11 Is Translational Medicine the Future of Therapy?
11.1 What Does the Future Hold for Translational Medicine?
11.2 Fixing the R&D Paradigm
11.3 Patient-Centered Healthcare
11.4 The Geography of Change
11.5 The Future of Therapy
Index
